1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
BUSINESS
Shionogi Logs Record Profits as Xocova Nets 100 Billion Yen from Govt Purchase: April-December
Shionogi delivered sharp revenue growth and record profits in April-December 2022 as it hauled in sales of 100 billion yen from the government purchase of its COVID-19 pill Xocova (ensitrelvir), according to its earnings released on January 30. In…
To read the full story
Related Article
- Shionogi’s H1 Sales Dip on One-Off Factor, HIV Franchise Grows
October 29, 2024
- Shionogi Renews Record Earnings in FY2023, Driven by Xocova and Xofluza
May 14, 2024
- Shionogi Notches Record Earnings in April-September, Xocova Drives Growth
November 1, 2023
- Shionogi Logs Record Earnings Q1 on Xocova, ADHD License Transfer
August 1, 2023
- Xocova’s Uptake in Japan in Line with Expectations: Shionogi CEO
May 11, 2023
- Shionogi Hits Record High Earnings on Xocova Boon in FY2022
May 11, 2023
- Shionogi’s H1 Operating Profit Sinks 33.8% on COVID-Linked R&D Expenses
November 1, 2022
- Shionogi Eyes PIII Topline Readout for COVID Pill in Aug-Sept., Sticks to H1 Approval Plan
August 2, 2022
- Shionogi’s Q1 Sales Up 4.2% on HIV Franchise, FX
August 2, 2022
- Shionogi’s Sales Rise 12.8% in FY2021 on Cefiderocol Growth in US/Europe
May 12, 2022
- Shionogi Books 110 Billion Yen Sales for Yet-to-Be-Approved COVID Pill, Vaccine: FY2022 Outlook
May 12, 2022
- Shionogi Ups FY2021 Earnings Outlook on HIV Patent Suit Settlement
April 26, 2022
- Shionogi’s April-Dec. Operating Profit Tumbles 40%-Plus on Antibiotic Promotion, COVID R&D
February 1, 2022
- Shionogi’s H1 Sales Wane 2.3% as Crestor Royalties Almost Disappear
November 2, 2021
- Shionogi Sees Sales Dip in Q1 despite Japan Growth; Crestor Royalty Nearly Zero
August 3, 2021
- Shionogi Incurs Double-Digit Sales Fall in FY2020 as Infectious Disease Meds Falter
May 11, 2021
- Shionogi Sees Double-Digit Sales Decline in April-December as Infectious Disease Meds Suffer
February 2, 2021
- Shionogi Sales Sag 9.3% in April-September on COVID-19, Price Cuts
November 2, 2020
- Shionogi Suffers Double-Digit Dip on Q1 Earnings as COVID-19 Weighs
August 3, 2020
BUSINESS
- 680 Employees Exit Takeda in Buyout Program, 10%-Plus of Japan Staff
March 4, 2025
- Novartis Bags Global Rights to Kyorin’s MRGPRX2 Antagonist
March 4, 2025
- Australia Rejects Lecanemab Again, Eisai to Challenge Decision
March 4, 2025
- Blackstone to Buy 60% Stake in Japan CRO CMIC
March 4, 2025
- Alfresa to Build New Cell Therapy CDMO Site in Japan
March 4, 2025
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…